Antibody-Drug Therapeutic Conjugates: Potential of Antibody-Sirnas in Cancer Therapy Publisher Pubmed



Yarian F^{1, 2} ; Alibakhshi A^{1, 2} ; Eyvazi S^{1, 2} ; Arezumand R³ ; Ahangarzadeh S⁴ Show Affiliations
Source: Journal of Cellular Physiology Published:2019

Abstract

Codelivery is a promising strategy of targeted delivery of cytotoxic drugs for eradicating tumor cells. This rapidly growing method of drug delivery uses a conjugate containing drug linked to a smart carrier. Both two parts usually have therapeutic properties on the tumor cells. Monoclonal antibodies and their derivatives, such as Fab, scFv, and bsAb due to targeting high potent have now been attractive candidates as drug targeting carrier systems. The success of some therapeutic agents like small interfering RNA (siRNA), a small noncoding RNAs, with having problems such as enzymatic degradation and rapid renal filtration need to an appropriate carrier. Therefore, the aim of this study is to review the recent enhancements in development of antibody drug conjugates (ADCs), especially antibody–siRNA conjugates (SRCs), its characterizations and mechanisms in innovative cancer therapy approaches. © 2019 Wiley Periodicals, Inc.